BRAF and melanoma: In addition, the BRAF inhibitor, vemurafenib, has not been considered as a common treatment option for patients with mucosal melanoma, as BRAF mutations have been identified much less frequently in patients with mucosal melanoma compared with those arising from cutaneous surfaces (24,25).